DISCO Pharmaceuticals GmbH

Looking ahead, there’s lots of optimism in the sector as noted in Melanie Senior recent article ‘Biotech financing: darkest before the dawn’ published in Nature Portfolio's Biotechnology. Alongside other notable events, DISCO Pharmaceuticals GmbH’s €20m seed financing suggests the sector is headed in the right direction. Read the full article here 👉 https://lnkd.in/eWXV2y3q

Sometimes you need to retreat from the spotlight and relax a little bit.    And that’s exactly what we did.   For this year’s offsite #CompanyRetreat, DISCO team members from Cologne and Zurich sashayed their way to Karlsruhe, a sun-soaked☀ city full of rich culture and tradition situated between the Rhine and the Black Forest🌲in southwest Germany.   We kicked off the retreat with a little bit of reflection to discuss what we have achieved so far and what will be our focus for the next year.   However, we also had plenty of time to relax and get to know each other beyond the science🔬. We connected over delicious tapas, football ⚽ and a treasure hunt💰through the city centre tested our #teambuilding skills and fortified our competitive nature and drive.   We are rested and recharged, ready to continue our mission in transforming cancer care.   #mentalhealth #wellness #collaboration

Today on World Lung Cancer Day, we want to raise awareness of the most aggressive form of lung cancer: Small Cell Lung Cancer (#SCLC). At DISCO Pharmaceuticals GmbH, using our target discovery platform, we have completed the first-ever mapping of the SCLC #surfaceome. This has revealed countless novel proteins and protein communities on the surface of SCLC cells providing target🎯candidates for mono- and bi-specific #antibodytherapeutics Using this knowledge, we have launched the development of SCLC target-specific therapeutics to improve #patient care by providing more effective, targeted treatment options. To learn more about our cell surfaceome discovery technology, visit the link in the comments below. #WorldLungCancerDay #WLCD2024 #LungCancerAwareness #SmallCellLungCancer

Our CEO, Roman Thomas, recently spoke🎙to Janelle Hart, Managing Editor at Citeline, following his recognition as one of In Vivo's Rising Leaders earlier this year. The article published today, Roman outlines the background behind DISCO Pharmaceuticals GmbH Pharmaceuticals, our target🎯discovery platform technology and its potential to redefine cancer drug discovery.   You can read the article📰using the link in the comments below.    #InVivosRisingLeaders2024

📰 Extra! Extra! Read all about it! 📰   In the latest article for Drug Target Review, our CEO Roman Thomas describes how DISCO Pharmaceuticals GmbH - The #Surfaceome Company, uses its disruptive technology to comprehensively map the surface proteins of cancer cells in search of new targets for novel cancer drugs.    To learn more about DISCO and how its cutting-edge technology could change the future of cancer-targeted therapies of all modalities, including #ADCs, #Tcell engagers, #CARTcells and #radiopharmaceuticals, read the full article here 👉 https://bit.ly/3W1QK0x

Congratulations Ruedi Aebersold on achieving this high honour! Ruedi will be awarded the Dr H.P. Heineken Prize for Biochemistry and Biophysics. Your contributions to science and the #proteomics field have been outstanding. You keep setting the bar high and leaping right over it!   We are grateful to have you as a member of our Scientific Advisory Board.   On the 60th anniversary of the Heineken Prizes, the jury has decided to nominate not one but two top scientists to receive the Dr H.P. Heineken Prize for Biochemistry and Biophysics. A Congratulations to both Ruedi Aebersold and Matthias Mann!    #heinekenprizes #surfaceome #drugdiscovery

We are proud to announce that our CEO, Roman Thomas, has been nominated as a finalist for the Andreas & Thomas Strüngmann Award! DISCO Pharmaceuticals GmbH is rooting for you!

DISCO Pharmaceuticals GmbH is #hiring!    We have a great opportunity for a Lab Technician to join the DISCO Target Validation and #DrugDiscovery team. We are identifying new druggable targets by mapping the #surfaceome of cancer cells using our disruptive discovery platform and leveraging this unique insight into advancing the development of novel #antibody therapeutics for cancer indications with a high unmet medical need.    A successful candidate will be based at our Cologne site and should be a skilled MTA, BTA or have an equivalent degree along with 3 years of practical experience, preferably in a #biotech or #pharma setting.    If you are interested in joining our dynamic and highly motivated team in a stimulating and inspiring environment, please send your CV, along with a covering letter using the link below.    Apply here: https://bit.ly/4dAectw   #antibodies #anitbodytherapeutics

DISCO Pharmaceuticals GmbH is #hiring!    We have a great opportunity for a Lab Technician to join the DISCO Target Validation and #DrugDiscovery team. We are identifying new druggable targets by mapping the #surfaceome of cancer cells using our disruptive discovery platform and leveraging this unique insight into advancing the development of novel #antibody therapeutics for cancer indications with a high unmet medical need.    A successful candidate will be based at our Cologne site and should be a skilled MTA, BTA or have an equivalent degree along with 3 years of practical experience, preferably in a #biotech or #pharma setting.    If you are interested in joining our dynamic and highly motivated team in a stimulating and inspiring environment, please send your CV, along with a covering letter using the link below.    Apply here: https://bit.ly/4dAectw   #antibodies #anitbodytherapeutics

Our Co-Founder and CEO, Roman Thomas will be in San Sebastian, Spain on 12-14 May for #BioEquityEurope2024. Roman will give a company presentation on DISCO Pharmaceuticals GmbH revolutionary surface #proteomics platform and how it is used to identify novel cancer targets on the cell surface at scale for the development of first-in-class drugs.   📅Monday 13 May | 17:10 – 17:19 | Room 9 | Cancer Track   Please get in touch if you would like to meet with Roman and to learn how DISCO has successfully mapped the first ever #surfaceome of a cancer type, #SmallCellLungCancer (#SCLC). Use the links in the comments below.    #BioEquityEurope #surfaceome #drugdiscovery